Epithelial overexpression of IL-33 induces eosinophilic esophagitis dependent on IL-13
Eosinophilic esophagitis (EoE) is an increasingly common inflammatory condition of the esophagus; however, the underlying immunologic mechanisms remain poorly understood. The epithelium-derived cytokine IL-33 is associated with type 2 immune responses and elevated in esophageal biopsies from EoE subjects. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 2, 2024 Category: Allergy & Immunology Authors: Mia Y. Masuda, Grace C. Pyon, Huijun Luo, William E. LeSuer, Arina Putikova, Adelyn Dao, Danna R. Ortiz, Aliviya R. Schulze, Nicholas Fritz, Takao Kobayashi, Koji Iijima, Andres J. Klein-Szanto, Masataka Shimonosono, Samuel Flashner, Masaki Morimoto, Rish Source Type: research

Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to < 12 Years: Results from a Phase 3 Double-Blind Vehicle-Controlled Study
Ruxolitinib cream was effective and well tolerated to 8 weeks in a phase 3 study of children 2 – (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Weily Soong, Andrea Zaenglein, Megha Tollefson, Eric Simpson, Alim Devani, Joel Joyce, Douglass Forsha, Joel Schlessinger, Howard Kallender, Brett Angel, Qian Li, Amy Paller Source Type: research

Common Contact Allergens among Hispanics at an Allergy Academic Center: The Emergence of Acrylates
Allergic contact dermatitis is a cause of significant morbidity and has important occupational and clinical implications. Acrylates have been recognized as rising allergens in the last few years given the widespread use of these chemicals in the nail industry and cosmetics, yet most published series do not include acrylates within the most common allergens. Limited data exists on allergen sensitization patterns among the Hispanic pediatric and adult populations. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Nicole Sosa-Castellanos, Sylvette Nazario Source Type: research

Novel Bradykinin Detection In The Diagnostic Workup Of Patients With Recurrent Angioedema Attacks
Recurrent angioedema etiology can be bradykinin-mediated angioedema (BK-AE) or more commonly through mast cell activation. However, BK-AE can be potentially fatal if acute laryngeal symptoms are undiagnosed or untreated. Establishing a consistent diagnostic measurement of bradykinin for recurrent angioedema patients can distinguish between the two pathways, providing optimized therapy. The study goal was to use liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantitatively measure bradykinin and detect differences between patients with Hereditary Angioedema (HAE) versus non-histaminergic idiopathic angioedema ...
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Yunkou Wu, Frank Lichtenberger, Joseph Chiao, Lili Wan, Joanna Yu, Jing Yu, Alex Chi, Maggie Xu, Huamin Li Source Type: research

The age of eczema onset increases the risk of multiple food allergies.
This study aims to characterize the prevalence, related factors of eczema, and age of eczema onset in relation to FA outcomes within a cohort of children with FA. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: H. Hikma Abbas, Mahboobeh Mahdavinia, Jialing Jiang, Mark Wlodarski, Lucy Bilaver, Amal Assa'ad, Hemant Sharma, Ruchi Gupta, Aame Betty Andy-Nweye, Dina Naquiallah Dina Naquiallah, Susan Fox, Zainab Al-Obaidi, Donyea Moore Source Type: research

The Impact of Donidalorsen Taken Every 8 Weeks in Patients With Hereditary Angioedema: Two-Year Update
The phase 2 open-label extension (OLE) study (NCT04307381) of donidalorsen in patients with Type 1/2 hereditary angioedema (HAE) demonstrated a 76% reduction in monthly attack rate and improved quality-of-life (QoL) with every 8 weeks (Q8W) dosing at Year 1. The Year 2 results of patients who received donidalorsen Q8W are presented. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Michael Manning, Laura Bordone, Kenneth Newman, Yiwen Deng, Veronica Alexander, Steve Dorow, Marc Riedl, Eugene Schneider, Danny Cohn Source Type: research

Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines
Chronic spontaneous urticaria (CSU) negatively impacts patients ’ quality of life (QoL). The Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) captures physical, psychosocial, and practical domains of QoL in CSU patients. The current analysis evaluated the effect of dupilumab on CU-Q2oL items in omalizumab-naïve CSU patients inadequately controlled wi th H1 antihistamines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Thomas Casale, Gil Yosipovitch, Sarbjit Saini, Moshe Ben-Shoshan, Lisa Beck, J érôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang Source Type: research

Dupilumab Improves Dermatology-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1 Antihistamines
Chronic spontaneous urticaria (CSU) is characterized by wheals, angioedema, or both recurring for>6 weeks, affecting patients ’ quality of life (QoL). Here we report the effect of dupilumab on dermatology-specific QoL as measured by the Dermatology Life Quality Index (DLQI) in omalizumab-naïve CSU patients inadequately controlled with H1 antihistamines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Thomas B. Casale, Lisa A. Beck, Sarbjit Saini, Moshe Ben-Shoshan, Gil Yosipovitch, J érôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang Source Type: research

Consistently Low Hereditary Angioedema Attack Rates with Berotralstat Regardless of Prior Prophylaxis: Real-World Outcomes
Consistently low hereditary angioedema (HAE) attack rates were observed in patients who switched to berotralstat monotherapy in the APeX-S study.1 Here, we present real-world effectiveness data for patients who initiated berotralstat in the United States and were previously on another prophylactic therapy. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marc Riedl, Cristine Radojicic, Douglas Johnston, Meri LiVecchi, Lindsey Noble, Stephanie Wasilewski, Tyler Nadig, Jonathan Bernstein Source Type: research

Remibrutinib Treatment Has No Impact on Blood Counts in Patients With Chronic Spontaneous Urticaria: Results From Phase 2b 52-week Extension Study Results
Remibrutinib (LOU064), a highly selective oral Bruton ’s tyrosine kinase inhibitor, has shown efficacy and a favorable safety profile in patients with chronic spontaneous urticaria in a preceding core study. Here, we report change from baseline (CFB) in blood cell counts from the Phase 2b 52-week extension study. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Alexander Greiner, Vipul Jain, Ana Gim énez-Armau, Jeffrey Tillinghast, Karine Lheritier, Pauline Walsh, Sibylle Haemmerle, Artem Zharkov, Robert Snyder Source Type: research

Population Pharmacokinetic/Pharmacodynamic Analysis Of Garadacimab, In Patients With Hereditary Angioedema
Garadacimab (anti-activated factor XII monoclonal antibody) is being evaluated for long-term prophylaxis of hereditary angioedema (HAE). Inhibition of FXIIa-mediated kallikrein activity can be used as a measure of garadacimab effect. We assessed the pharmacokinetic (PK)/pharmacodynamic (PD) relationship between garadacimab concentration and FXIIa-mediated kallikrein activity, and the impact of intrinsic/extrinsic factors in population subgroups. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Fiona Glassman, Ankur Sharma, Shen Cheng, Curtis Johnston, Bernardo De Miguel Lillo, John-Philip Lawo, Iris Jacobs, Daniel Polhamus, Partha Nandy Source Type: research

Dupilumab-induced Conjunctivitis In Atopic Dermatitis Patients Is Associated To An Increase Of Proinflammatory Molecules In Tears.
Dupilumab (DU) is an effective treatment in both atopic dermatitis (AD) and T2 asthma (AS) patients, but is associated to ocular surface alterations in AD subjects only. This side effect might be associated to differences in the immunological infiltration. We investigate the clinical and immunological features in tears of DU-associated conjunctivitis. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Carlos Aranda, Carmen Alba, Gustavo Garriga, Laura Zubiaga, Almudena Testera-Montes, Cristobalina Mayorga, Enrique Herrera, Maria Torres Jaen, Jorge Suarez, Ibon Eguiluz Source Type: research

Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes
Berotralstat, a once-daily oral prophylactic therapy for hereditary angioedema (HAE), demonstrated sustained reductions in HAE attack rates in clinical trials.1 Here, we report real-world effectiveness data for patients who initiated berotralstat in the United States. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Mark Davis-Lorton, Donald Levy, Douglas Johnston, Meri LiVecchi, Lindsey Noble, Stephanie Wasilewski, Tyler Nadig, William Lumry Source Type: research

Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
The effect of the inhibition of type 2 inflammation by dupilumab on stratum corneum (SC) lipids responsible for skin barrier function in children with atopic dermatitis (AD) has not been evaluated. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Irina Bronova, Evgeny Berdyshev, Elena Goleva, Simon Danby, Anna Sofia Bronoff, Brittany Richers, Shannon Garcia, Marco Ramirez Gama, Patricia Taylor, Joseph Zahn, Inoncent Agueusop, Shantanu Bafna, Mark Boguniewicz, Peck Ong, Annie Zhang, Michael Cork, D Source Type: research

Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Disease Severity And Age Subgroups In The Treatment Of Adults And Children Down To 2 Years Of Age With Moderate To Severe Atopic Dermatitis
Atopic dermatitis (AD) presents a spectrum of clinical phenotypes. Here, we report efficacy by baseline disease severity and age from ADORING 1 and 2, two phase 3, randomized, controlled trials of tapinarof cream 1% (VTAMA ®, Dermavant Sciences, Inc.). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Anna Tallman, Luz Fonacier, Mark Boguniewicz, Jason Ohayon, Phililp M. Brown, David Rubenstein, Jonathan Silverberg Source Type: research